| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Activity of Tipifarnib (R115777, Zarnestra™), a Farnesyl Transferase Inhibitor, in Previously Treated Metastatic Breast Cancer
|
Maung, Kavita
|
|
2002
|
3 |
2 |
p. 106-108
3 p.
|
article
|
| 2 |
Adjuvant Chemotherapy with Doxorubicin and Cyclophosphamide in Women with Rapidly Proliferating Node-Negative Breast Cancer
|
Jones, Stephen E.
|
|
2002
|
3 |
2 |
p. 147-152
6 p.
|
article
|
| 3 |
Breast Cancer Chemoprevention: Current Challenges and a Look Toward the Future
|
Fabian, Carol J.
|
|
2002
|
3 |
2 |
p. 113-124
12 p.
|
article
|
| 4 |
Can We Afford to Cure?
|
Sledge Jr., George W.
|
|
2002
|
3 |
2 |
p. 91-
1 p.
|
article
|
| 5 |
Erratum
|
|
|
2002
|
3 |
2 |
p. 159-
1 p.
|
article
|
| 6 |
2002 Highlights from: 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 18–21, 2002
|
D'Orazio, Amy I.
|
|
2002
|
3 |
2 |
p. 94-98
5 p.
|
article
|
| 7 |
Improvement in Disease-Free Survival with Doxorubicin/Docetaxel/Cyclophosphamide (TAC) Versus 5-Fluorouracil/Doxorubicin/Cyclophosphamide (FAC) as Adjuvant Therapy for Node-Positive Breast Cancer
|
D'Orazio, Amy I.
|
|
2002
|
3 |
2 |
p. 103-105
3 p.
|
article
|
| 8 |
Is There a Role for Monitoring Circulating HER2?
|
Hayes, Daniel F.
|
|
2002
|
3 |
2 |
p. 136-137
2 p.
|
article
|
| 9 |
Prognostic Value of the Urokinase-Type Plasminogen Activator, and its Inhibitors and Receptor in Breast Cancer Patients
|
Borstnar, S.
|
|
2002
|
3 |
2 |
p. 138-146
9 p.
|
article
|
| 10 |
The HER2 Extracellular Domain as a Prognostic and Predictive Factor in Breast Cancer
|
Andrade Nunes, Raquel
|
|
2002
|
3 |
2 |
p. 125-135
11 p.
|
article
|
| 11 |
The Study of Tamoxifen and Raloxifene: Preliminary Enrollment Data from a Randomized Breast Cancer Risk Reduction Trial
|
Vogel, Victor G.
|
|
2002
|
3 |
2 |
p. 153-159
7 p.
|
article
|
Journal description